Enlibrium Secures $15,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0ca8108f-f166-4a77-a7bf-04bbfe24e2a5 - Date
12/4/2015 - Company Name
Enlibrium - Mailing Address
Undisclosed San Diego, CA 92130 USA - Company Description
Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$15,000,000 - Transaction Round
Series A - Proceeds Purposes
The financing is expected to provide sufficient capital to advance Enlibrium’s lead compounds through Phase 1 clinical trials. - M&A Terms
- Venture Investor
Avalon Ventures - Venture Investor
TPG Biotech - Venture Investor
Correlation Ventures - Venture Investor
Osage Partners
